Compare TG Therapeutics Inc (TGTX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TotalEnergies SE — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while TotalEnergies SE trades at $86.11 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 23.5× TG Therapeutics Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and TotalEnergies SE for 90 Days on average.
| TGTX | TTE | |
|---|---|---|
Market Cap | $8.16B | $191.82B |
Volume | 1,735,121 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $59.06 | $93.60 |
52-Week Low | $26.94 | $57.39 |
Typical Hold Time | 16 Days | 90 Days |
Enterprise Value | $8.37B | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
TotalEnergies (TTE) trades at $86.02, up 2.13% today, with a bearish technical signal but strong fundamentals including a P/E of 10.77 and ROE of 14.56%. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a $10 billion investment in Argentina and increased share buybacks to $2.5 billion, signaling growth commitment. Cash flow trends show a recovery to positive net cash flow in 2025 after declines in prior years.
The outlook is positive with a consensus price target of $95.33, representing 10.8% upside, supported by 55.88% analyst buy ratings. Risks include declining revenue from $263.3B in 2022 to $182.3B in 2025 and rising debt-to-asset ratio to 20.17% in 2025. Strategic investments in LNG and power diversification offer long-term growth, but oil price volatility and execution risks remain key concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
